Best of ASCO GU 2016 prostate cancer data

Prof Clarke (The Christie Hospital, Manchester, UK) chairs a discussion with Dr Payne (University College Hospital, London, UK) and Prof Iversen (Copenhagen Prostate Cancer Center, Copenhagen, Denmark) for ecancertv about the highlights in prostate treatment arising from ASCO GU 2016.

They discuss the results and implications of data coming from RTOG 0415, a randomised phase III non-inferiority study which compared two fractionation schedules in patients with low-risk prostate cancer, as well as the CHHiP trial which compared hypofractionated high-dose intensity-modulated radiotherapy schedules.

They consider the optimal treatment schedules for salvage patients and touch upon the Early Prostate Cancer (EPC) trial with bicalutamide, noting their observations between the two trials.

With regards to the STAMPEDE trial, they discuss and explore different rationales for the surprising overall survival advantage.

This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).